General Clinical Chemistry Analyzers and Accessories
Abcam CHIR-124, 50MG
MW 419.9 Da, Purity >98%. Novel and potent Chk1 inhibitor (IC₅₀ = 0.3 nM), 2,000-fold more potent than Chk2 (IC₅₀ = 0.7 μM). Also, potently targets other kinases such as FLT3 (IC₅₀ = 5.8 nM), PDGFR (IC₅₀ = 6.6 nM), GSK-3 (IC₅₀ = 23.3 nM) and Fyn (IC₅₀ = 98.8 nM) .
The product is subject to the following: Abcam Restricted Use Statement
Abcam SRT1720 hydrochloride, 5MG
MW 506 Da, Purity >=98%. Selective SIRT1 activator (EC₅₀ = 0.16 μM), 230-fold less potent for SIRT2 and SIRT3. Induce autophagy.
The product is subject to the following: Abcam Restricted Use Statement
Abcam URMC-099, 25MG
MW 421.5 Da, Purity >98%. Novel orally bioavailable, brain penetrant mixed lineage kinase (MLK) inhibitor (IC₅₀ values of 19, 42, 14, and 150 nM for MLK1, MLK2, MLK3, and the related MLK family member DLK, respectively). Inhibits multiple kinase pathways including LRRK2 (IC₅₀ = 11 nM). Decreases the production of inflammatory cytokines in cultured microglia exposed to HIV-1 Tat. Reduces fMLP-induced chemotaxis of neutrophil from wild-type C57Bl/6 mice. Facilitates Amyloid-β Clearance in a Murine Model of Alzheimer's Disease.
The product is subject to the following: Abcam Restricted Use Statement
Abcam Miglustat hydrochloride, 1MG
MW 255.74 Da, Purity >=98%. An inhibitor of the N-linked oligosaccharide processing enzymes α-glucosidase I and II. It inhibits rat testicular enzymes ceramide-glucosyltransferase and beta-glucosidase 2 with IC₅₀ values of 32 and 81 μM respectively. Miglustat is used for the treatment of type 1 Gaucher's disease. It is an inhibitor of HIV replication in vitro. It shows activity against SARS-CoV-2 in vitro with EC₅₀ values in the micromolar range.
The product is subject to the following: Abcam Restricted Use Statement
Abcam GW-311616A, 5MG
MW 434 Da, Purity >=98%. A potent and selective intracellular neutrophil elastase (NE, alpha-1-proteinase) inhibitor. Inhibits human neutrophil elastase (HNE) and is selective over other human serine proteases with IC₅₀ values of 22 nM for HNE, >100 μM for trypsin, cathepsin G and plasmin, >3 μM for chymotrypsin and tissue plasminogen activator.
The product is subject to the following: Abcam Restricted Use Statement
Abcam Ponesimod, sphingosine-1-phophate receptor agonist, 5MG
MW 461 Da. Ponesimod is a potent agonist of sphingosine-1-phophate receptor. (S1P₁/EDG-1; IC₅₀s = 6, >10,000, 2,068, 1,956, and 142 nM for S1P₁-S1P₅, respectively, in a radioligand binding assay). Selectively activates S1P₁ in a GTPγS assay (EC₅₀s = 5.7, >10,000, 105, 1,108, and 59.1 nM, for S1P₁-S1P₅, respectively).
The product is subject to the following: Abcam Restricted Use Statement
Abcam GSK-690693 hydrochloride, ATP-competitive pan-Akt kinase inhibitor, 5MG
MW 425.5 Da, Purity >99%. Novel ATP-competitive pan-Akt kinase inhibitor (IC₅₀ values are 2, 13 and 9 nM for Akt1, 2 and 3 respectively). Also exhibits some inhibition of AMPK, PKA and PAK and PKC isoforms (IC₅₀ < 100 nM). Displays antiproliferative and apoptotic effects in tumor cell lines.
The product is subject to the following: Abcam Restricted Use Statement
YSI 3P LifeScience 2754 Glutamate Membranes (4 ea)
Glutamate Membranes. Used to measure glutamate on YSI 2700, and 2900 Series Analyzers.
Abcam LGK974, 5MG
MW 396.4 Da, Purity >=98%. LGK-974 is a potent and specific inhibitor of Porcupine (porcn), a Wnt-specific acyltransferase (IC₅₀ = ~0.4 nM). GK974 potently inhibits Wnt signaling, has strong efficacy in rodent tumor models, and is well-tolerated. In addition, head and neck cancer cell lines with loss-of-function mutations in the Notch signaling pathway have a high response rate to LGK974.
The product is subject to the following: Abcam Restricted Use Statement
Abcam G10, STING signaling activator, 5MG
MW 430.9 Da, Purity >98%. G10 is an indirect activator or stimulator of interferon genes (STING) signaling. It induces transcription of genes dependent on IRF3 and IFN, which are activated by STING, but has no effect on non-STING activated NF-κB-dependent transcription of IL-8, IL-1β, or MIP-1α in human fibroblasts. However, G10 does increase expression of NF-κB-dependent genes in human peripheral blood mononuclear cells (PBMCs) and human umbilical microvascular endothelial cells (HUMECs). In vitro, it prevents replication of the chikungunya and Venezuelan equine encephalitis alphaviruses (IC₉₀s = 8.01 and 24.57 μM, respectively). G10 (100 μM) increases phosphorylation of IRF3, which is lost in cells lacking STING.
The product is subject to the following: Abcam Restricted Use Statement
Abcam BIIB 021, 25MG
MW 318.76 Da, Purity >98%. Selective, Hsp90 competitive inhibitor (Ki = 1.7 nM). Displays no significant activity at a range of ATP-binding kinases or Na+K+ ATPase. Induces degradation of HER-2 in vitro (EC₅₀ = 38 nM in MCF-7 cells). Inhibits growth and promotes cell death in a variety of human tumor cells. Orally bioavailable.
The product is subject to the following: Abcam Restricted Use Statement
Abcam GW-311616A, 1MG
MW 434 Da, Purity >=98%. A potent and selective intracellular neutrophil elastase (NE, alpha-1-proteinase) inhibitor. Inhibits human neutrophil elastase (HNE) and is selective over other human serine proteases with IC₅₀ values of 22 nM for HNE, >100 μM for trypsin, cathepsin G and plasmin, >3 μM for chymotrypsin and tissue plasminogen activator.
The product is subject to the following: Abcam Restricted Use Statement
Abcam GSK2656157, 5MG
MW 416.5 Da, Purity >=98%. Potent and selective PERK inhibitor (IC₅₀ = 0.9 nM in cell-free assay). ATP-competitive. Exibits 500-fold selectivity for PERK versus a panel of 300 kinases.
The product is subject to the following: Abcam Restricted Use Statement
Abcam CCG 1423, Rho pathway-mediated signaling inhibitor, 5MG
MW 454.7 Da, Purity >98%. Specific inhibitor of Rho pathway-mediated signaling and activation of serum response factor (SRF) transcription. Displays activity in several in vitro cancer cell functional assays. Potently (<1 mumol/L) inhibits lysophosphatidic acid-induced DNA synthesis in PC-3 prostate cancer cells, inhibits growth of RhoC-overexpressing melanoma lines at nanomolar concentrations. Selectively stimulates apoptosis of the metastasis-prone, RhoC-overexpressing melanoma cell lines. Acts at or downstream of MLK1 and upstream of SRF. Blocks MLK1 nuclear localization.
The product is subject to the following: Abcam Restricted Use Statement